Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 annual meeting was held from July 10 to 12, 2025, in Bogotá, Colombia. It was attended by 206 rheumatologists, dermatologists, trainees, patient research partners, representatives of patient organizations, industry partners, and others. Here we provide an overview of the workshops and symposia featured at the GRAPPA 2025 annual meeting and introduce the manuscripts published together in this supplement as a meeting report.
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) held its 2025 annual meeting July 10-12 in Bogotá, Colombia. The meeting was attended by 206 rheumatologists, dermatologists, radiologists, representatives from biopharmaceutical industry, trainees, patient research partners (PRPs), representatives from patient organizations, and others (Table).
Groups of attendees at the GRAPPA 2025 annual meeting, Bogotá, Colombia.
Reports from the various sessions and main topics are presented in this supplement of The Journal of Rheumatology. Once again, Young-GRAPPA (Y-GRAPPA) members co-authored several of the manuscripts as an opportunity for manuscript writing under the supervision of the senior authors.
Prior to the beginning of the formal meeting, PRPs had their meeting while Y-GRAPPA members met with mentors. Attendees of the industry research collaboration meeting heard from Drs. Andrew Blauvelt and Philip Mease about the latest update on novel approaches in the management of psoriasis (PsO) and psoriatic arthritis (PsA).1
Two concurrent workshops were offered on the first day of the formal meeting. A workshop on magnetic resonance imaging in PsA, which focused on axial disease, was presented by Drs. Catherine Bakewell and Manouk De Hooge,2 and a workshop on topicals for rheumatologists was presented by Drs. Juan Raul Castro-Ayarza and Manuel Franco.3
Following the introduction of the meeting by the 2 co-presidents of GRAPPA, Drs. Arthur Kavanaugh and Joseph Merola, a symposium on the role of glucagon-like peptide-1 (GLP-1) therapies in psoriatic disease (PsD) was presented. It began with a presentation by Dr. Daniel Drucker, followed by the PRP perspective on weight loss and presentations on managing GLP-1 care by Drs. Enrique Soriano and Anthony Fernandez representing rheumatology and dermatology, respectively.4
The annual trainee symposium, organized by Drs. Elaine Husni, Sibel Aydin Zehra, and Lihi Eder, included 5 oral presentations. These ranged from skin-to-synovium migration of immune cells, treat-to-target management to sustain low disease activity, GLP-1 receptor agonist effect on cardiovascular disease in PsO, a unique PsO phenotype, and physical activity and risk for development of PsA. In addition, 16 posters were presented during the lunch hour and represented varied topics related to PsD from rheumatology and dermatology trainees.5 Poster tours took place during the lunch hour of the second day.
The afternoon program started with a new type of session, labeled “soapbox,” which consisted of short presentations. This session included a presentation on Centers of Excellence for PsD in Latin America, a report on drug survival in Latin America, and the role of digital biomarkers and artificial intelligence (AI) in predicting PsA progression.6
Presentations of previously awarded GRAPPA pilot research grants followed. These included the role of neutrophil hypoxia-inducible factor 1α (HIF1A) in PsA, potential biomarkers predicting response to therapy in PsA, bone properties and biomechanics in PsA, understanding body composition, and the effect of sleep on PsO disease severity.7
The trainee awards recognition and dinner took place at the end of the first day. During the dinner, there were presentations on dermatology (Dr. Angela Londono) and rheumatology (Dr. Wilson Bautista-Molano) collaboration in South America.
The second day of the GRAPPA meeting began with 2 concurrent sessions. The first was a unique session entitled “Bridging Generations,” focusing on leveraging technology and AI for research and practice,8 and the second was a session on drug-induced rashes, focusing on immune shifts in PsD.9
A session on geographic variation in PsD care and resource limitation included reports from Singapore, the United States, Colombia, and Türkiye, as well as a patient perspective from Kenya.10
A basic science presentation by Dr. Christopher Ritchlin focused on synovial immunopathology and considered how novel technologies such as single-cell and spatial omics uncover disease-specific synovial landscapes in rheumatoid arthritis and PsA.11
A second soapbox session included presentations on depression, the epidemiology of PsD in Peru, and an AI model for predicting a difficult-to-treat/manage course in patients with PsA.12
Drs. Alexis Ogdie and Gary Macfarlane discussed the opportunities and challenges of gleaning data from administrative databases.13
The GRAPPA debate between Dr. William Tillett (in favor) and Dr. Arthur Kavanaugh (against) involved a GRAPPA discussion on the necessity for plain radiographs in the assessment of patients with PsA.14
GRAPPA research projects were presented next. This included a report on the development of criteria for axial PsA from the Axial Involvement in Psoriatic Arthritis (AXIS) study and GRAPPA definitions of complex-to-manage and treatment-refractory PsA.15 Additionally, a proposed project from Y-GRAPPA, the Global Exploration of Psoriatic Arthritis Disease Activity Assessment (EXPLORE-PsA) study, was introduced.16
Conclusion
The GRAPPA 2025 annual meeting ended with closing remarks from the co-presidents. The meeting was successful, addressing a range of scientific discovery and dealt with issues that are relevant to the management of people with PsD. Attendees had the opportunity to participate in Bogotá City tours organized by GRAPPA, which added to the enjoyment of the meeting. The next meeting will be in Lisbon, Portugal on July 9-11, 2026.
Footnotes
FUNDING
Financial support to enable the GRAPPA 2025 annual meeting was provided by AbbVie, Acelyrin, Amgen, BI, BMS, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, and UCB.
COMPETING INTERESTS
DDG received consulting fees from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB; and research grants from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. WB received consulting and speaker fees from Novartis, Pfizer, Janssen, Biopas, Amgen, Eli Lilly, AbbVie, and GSK. DP received research support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; received consulting fees from AbbVie, Eli Lilly, Greywolf Therapeutics, Janssen, Merk, MoonLake, Novartis, Pfizer, and UCB; received speaker fees from AbbVie, Canon, Eli Lilly, Janssen, Medscape, Novartis, Peervoice, Pfizer, and UCB; and serves as a member of the GRAPPA steering committee. WT received research grants from AbbVie, Amgen, Eli Lilly, Janssen, Pfizer, and UCB; and consulting or speaker fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, GSK, Janssen, MSD, Novartis, Ono, Pfizer, UCB and Takeda. ABG received research/educational grants from Avalo, BMS, Janssen, MoonLake, and UCB (all paid to Mount Sinai School of Medicine until May 1, 2025); and honoraria/speakers fees as an advisory board member and consultant from Amgen, BMS, Eli Lilly, Highlight Therapeutics, Janssen, Novartis, Sanofi, Sun Pharma, Takeda, Teva, and UCB.
ETHICS AND PATIENT CONSENT
Institutional review board approval and patient consent were not required.
PEER REVIEW
As part of the supplement series GRAPPA 2025, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.
- Accepted for publication June 15, 2026.
- Copyright © 2026 by the Journal of Rheumatology
This is an Open Access article, which permits use, distribution, and reproduction, without modification, provided the original article is correctly cited and is not used for commercial purposes.
